Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in CKD Enabled by Chlorthalidone
NCT05222191Phase 2Unknown
- Sponsor
- Indiana Institute for Medical Research
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) comparing Spironolactone + Placebo with Spironolactone + Chlorthalidone (2 arms). Primary endpoint: Change in Systolic Automated Office Blood Pressure at 12 weeks. Status: unknown.
02
Drugs
chlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05222191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222191.